This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Announces Research Supporting VSEL(TM) Technology Presented At The American Society Of Hematology Annual Meeting

NEW YORK, Jan. 9, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), an emerging leader in the fast growing cell therapy market, announced today that multiple abstracts presented December 8-11 at the 2012 American Society of Hematology ("ASH") annual meeting, add to the growing body of scientific work describing the capabilities of very small embryonic-like stem cells ("VSELs™"). These papers are published as 2012 Annual Meeting Abstracts in the journal Blood, Volume 120, Issue 21.

"Cell therapy has the potential to radically change the face of how diseases are treated, leading to longer and, more importantly, better quality lives," said Dr. Robin Smith, CEO of NeoStem. "These abstracts include one authored by members of the NeoStem research and development team and three coauthored by Mariusz Z. Ratajczak, M.D., Ph.D., D.Sci., co-inventor of VSEL™ Technology and member of NeoStem's Scientific Advisory Board. NeoStem's technologies, including its VSEL™ Technology which is in pre-clinical development, are supporting this paradigm shift in medical treatment that we believe is underway and that is developing cell therapies through amplification of our own body's natural repair mechanisms; a shift toward treating disease with our own cells and toward finding cures, as opposed to treating the symptoms of illnesses. The potentially broad application of our VSEL™ Technology could lead to the treatment of a wide-range of serious medical conditions, including macular degeneration, acute radiation syndrome, wounds, periodontitis and even osteoporosis."

The VSEL™-related ASH abstracts include:
  • "A Lin-CD45-CD34+ Population of Extracellular Vesicles in Human Blood that Mimics Very Small Embryonic-Like Stem Cells (VSELs) by Flow Cytometry," co-authored by David W. O'Neill, M.D., Director of Research and Development, Progenitor Cell Therapy ("PCT", a NeoStem company) and Yajuan Jiang, Ph.D., Director Research Operations and Senior Scientist, PCT, along with other colleagues from the NeoStem research and development team. This work highlights the importance of continuing efforts to fully characterize human VSELs™ and the use of well defined, highly purified populations for in vitro and in vivo studies to demonstrate therapeutic activities. In order to develop a cell therapy that is VSEL™-based, NeoStem is focused on developing more efficient and cost-effective methods to isolate these cells.  
  • Three abstracts coauthored by Mariusz Z. Ratajczak, M.D., Ph.D., D.Sci.. These abstracts further the research on murine VSEL™ capabilities, suggesting their potential to proliferate into hematopoietic stem cells as well as expand in vivo in bone marrow in response to toxic damage of the brain, as well as data indicating that prolonged strenuous exercise may cause bone marrow VSELs™ to proliferate and mobilize into peripheral blood.  
  • An abstract from Yoshiaki Sonoda and colleagues at the Department of Stem Cell Biology and Regenerative Medicine, Kansai Medical University, Osaka, Japan describing a method for extracting VSEL™-like cells from bone and outlining work that begins to compare the properties of these bone-associated cells with bone marrow-derived VSELs™.

Dr. Smith further commented, "While still early, we believe there is much promise for VSELs™ and look forward to getting them into the clinic in order that we may explore their full potential and regenerative properties."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs